N-acetylglucosamine supplementation fails to bypass the critical acetylation of glucosamine-6-phosphate required for Toxoplasma gondii replication and invasion.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
20 Jun 2024
Historique:
received: 17 01 2024
accepted: 03 06 2024
medline: 20 6 2024
pubmed: 20 6 2024
entrez: 20 6 2024
Statut: aheadofprint

Résumé

The cell surface of Toxoplasma gondii is rich in glycoconjugates which hold diverse and vital functions in the lytic cycle of this obligate intracellular parasite. Additionally, the cyst wall of bradyzoites, that shields the persistent form responsible for chronic infection from the immune system, is heavily glycosylated. Formation of glycoconjugates relies on activated sugar nucleotides, such as uridine diphosphate N-acetylglucosamine (UDP-GlcNAc). The glucosamine-phosphate-N-acetyltransferase (GNA1) generates N-acetylglucosamine-6-phosphate critical to produce UDP-GlcNAc. Here, we demonstrate that downregulation of T. gondii GNA1 results in a severe reduction of UDP-GlcNAc and a concomitant drop in glycosylphosphatidylinositols (GPIs), leading to impairment of the parasite's ability to invade and replicate in the host cell. Surprisingly, attempts to rescue this defect through exogenous GlcNAc supplementation fail to completely restore these vital functions. In depth metabolomic analyses elucidate diverse causes underlying the failed rescue: utilization of GlcNAc is inefficient under glucose-replete conditions and fails to restore UDP-GlcNAc levels in GNA1-depleted parasites. In contrast, GlcNAc-supplementation under glucose-deplete conditions fully restores UDP-GlcNAc levels but fails to rescue the defects associated with GNA1 depletion. Our results underscore the importance of glucosamine-6-phosphate acetylation in governing T. gondii replication and invasion and highlight the potential of the evolutionary divergent GNA1 in Apicomplexa as a target for the development of much-needed new therapeutic strategies.

Identifiants

pubmed: 38900808
doi: 10.1371/journal.ppat.1011979
pii: PPATHOGENS-D-24-00119
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1011979

Informations de copyright

Copyright: © 2024 Alberione et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

María Pía Alberione (MP)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-University of Barcelona, Barcelona, Spain.

Víctor González-Ruiz (V)

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.

Olivier von Rohr (O)

Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.

Serge Rudaz (S)

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.

Dominique Soldati-Favre (D)

Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.

Luis Izquierdo (L)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

Joachim Kloehn (J)

Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.

Classifications MeSH